Ceftizoxime is a third-generation cephalosporin antibiotic used in the treatment of various bacterial infections, including lower respiratory tract infection, urinary tract infection, and gonorrhea. A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository.
- Mechanism
- Curator reviewed
Ceftizoxime is an aminothiazolyl cephalosporin with an extended spectrum of activity against many gram-negative, nosocomially acquired pathogens. It has excellent beta-lactamase stability, with good in vitro activity against Haemophilus influenzae, Neisseria gonorrhoeae and Klebsiella pneumoniae. Ceftizoxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that ceftizoxime interferes with an autolysin inhibitor.
- Primary indication
- Cetizoxime was previously indicated for the treatment of infections due to susceptible strains of bacteria.Curator reviewed · 1 structured indication
- Formula / weight
- C13H13N5O5S2 · 383.403 g/mol (avg)
- First approval
- Canada, 2001 · United States, 2006
- Code names
- FK 749 · FR 13749
- Brand names
Resolves to
NNULBSISHYWZJU-LLKWHZGFSA-NSMILES[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Ceftizoxime, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account